Seres Therapeutics (MCRB) News Today $0.88 -0.01 (-1.12%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Seres Therapeutics to highlight plans for SER-155 at JPMorgan conferenceDecember 17 at 12:41 PM | finance.yahoo.comSeres Therapeutics to Participate in 2025 J.P. Morgan Healthcare ConferenceDecember 16 at 7:00 AM | globenewswire.comSeres’ SER-155 gains breakthrough status for BSIs reductionDecember 11, 2024 | finance.yahoo.comOptimistic Buy Rating for Seres Therapeutics: Breakthrough Therapy Designation and Financial Stability Boost ConfidenceDecember 11, 2024 | markets.businessinsider.comSeres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to "Sell"StockNews.com downgraded shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday.November 27, 2024 | marketbeat.comSeres Therapeutics to Participate in Piper Sandler Healthcare ConferenceNovember 22, 2024 | globenewswire.comSeres Therapeutics Reports Q3 2024 Results and Strategic ProgressNovember 15, 2024 | markets.businessinsider.comPromising Developments and Financial Stability Drive Buy Rating for Seres TherapeuticsNovember 15, 2024 | markets.businessinsider.comSeres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...November 15, 2024 | finance.yahoo.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | msn.comSeres Therapeutics' (MCRB) Buy Rating Reaffirmed at Canaccord Genuity GroupCanaccord Genuity Group restated a "buy" rating and issued a $10.00 price objective on shares of Seres Therapeutics in a report on Thursday.November 14, 2024 | marketbeat.comSeres reports Q3 EPS from continuing operations (33c), consensus (24c)November 14, 2024 | markets.businessinsider.comSeres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 13, 2024 | markets.businessinsider.comSeres Therapeutics Q3 2024 Earnings PreviewNovember 13, 2024 | msn.comWhat's Next: Seres Therapeutics's Earnings PreviewNovember 13, 2024 | benzinga.comSeres Therapeutics (NASDAQ:MCRB) Stock, Option ChainNovember 10, 2024 | benzinga.comSeres Therapeutics (MCRB) to Release Earnings on WednesdaySeres Therapeutics (NASDAQ:MCRB) will be releasing earnings before the market opens on Wednesday, November 13, Zacks reports.November 7, 2024 | marketbeat.comSeres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024November 6, 2024 | globenewswire.comJP Morgan Downgrades Seres Therapeutics (MCRB)October 25, 2024 | msn.comSeres Therapeutics downgraded to Underweight from Neutral at JPMorganOctober 24, 2024 | markets.businessinsider.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) have earned a consensus rating of "Moderate Buy" from the three ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and two have given a buy ratingOctober 24, 2024 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Downgraded to Underweight at JPMorgan Chase & Co.JPMorgan Chase & Co. cut shares of Seres Therapeutics from a "neutral" rating to an "underweight" rating in a report on Thursday.October 24, 2024 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Stock Crosses Below Fifty Day Moving Average - Here's What HappenedSeres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50 Day Moving Average - Time to Sell?October 15, 2024 | marketbeat.comSeres Therapeutics files for resale of common stock by holderOctober 2, 2024 | msn.comSeres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.ASeptember 30, 2024 | globenewswire.comSeres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With NestléSeptember 27, 2024 | finance.yahoo.comSeres Therapeutics (NASDAQ:MCRB) Stock, Insider Trading ActivitySeptember 27, 2024 | benzinga.comSeres Therapeutics Stockholders Approve Sale Of VOWST Business To Societe Des Produits NestleSeptember 27, 2024 | markets.businessinsider.comSeres Therapeutics, Inc.: Seres Therapeutics Stockholders Approve Sale of VOWST to Nestlé Health Science; Sale Expected to Close on September 30September 27, 2024 | finanznachrichten.deSeres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30September 26, 2024 | globenewswire.comSeres Therapeutics' Strategic Sale Of Vowst Warrants A Rating UpgradeSeptember 23, 2024 | seekingalpha.comBuy Rating Affirmed for Seres Therapeutics Amid Strong Clinical Outcomes for SER-155September 14, 2024 | markets.businessinsider.comSeres reports positive results in infection prevention studySeptember 13, 2024 | uk.investing.comOppenheimer Sticks to Their Hold Rating for Seres Therapeutics (MCRB)September 13, 2024 | markets.businessinsider.comSeres Therapeutics (NASDAQ:MCRB) Rating Reiterated by Canaccord Genuity GroupCanaccord Genuity Group reaffirmed a "buy" rating and set a $10.00 target price on shares of Seres Therapeutics in a research report on Friday.September 13, 2024 | marketbeat.comSeres Therapeutics to Participate in Cantor 2024 Global Healthcare ConferenceSeptember 13, 2024 | globenewswire.comSeres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)September 12, 2024 | globenewswire.comSeres Therapeutics Target of Unusually High Options Trading (NASDAQ:MCRB)Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) was the recipient of some unusual options trading activity on Friday. Investors acquired 15,630 call options on the company. This is an increase of 824% compared to the typical daily volume of 1,692 call options.September 6, 2024 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50-Day Moving Average of $0.99Seres Therapeutics (NASDAQ:MCRB) Stock Crosses Below 50 Day Moving Average of $0.99August 29, 2024 | marketbeat.comBuy Rating Affirmed for Seres Therapeutics’ SER-155 Amid Anticipated Positive Impact on Infection and GvHD RatesAugust 22, 2024 | markets.businessinsider.comBrokers Offer Predictions for Seres Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:MCRB)Seres Therapeutics, Inc. (NASDAQ:MCRB - Free Report) - Investment analysts at Chardan Capital boosted their FY2024 earnings per share (EPS) estimates for shares of Seres Therapeutics in a research note issued on Wednesday, August 14th. Chardan Capital analyst K. Nakae now anticipates that the bioAugust 19, 2024 | marketbeat.comVanguard Group Inc. Buys 729,514 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB)Vanguard Group Inc. increased its stake in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB - Free Report) by 12.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 6,734,821 shares of the biotechnology company's stock after purchasing an additiAugust 18, 2024 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Expected to Post FY2025 Earnings of ($0.82) Per ShareSeres Therapeutics, Inc. (NASDAQ:MCRB - Free Report) - Chardan Capital issued their FY2025 earnings per share (EPS) estimates for shares of Seres Therapeutics in a research note issued to investors on Wednesday, August 14th. Chardan Capital analyst K. Nakae forecasts that the biotechnology companAugust 16, 2024 | marketbeat.comBuy Rating on Seres Therapeutics: Strategic Growth and Promising Clinical Trials Fuel Analyst ConfidenceAugust 15, 2024 | markets.businessinsider.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | msn.comSeres Therapeutics (NASDAQ:MCRB) Earns "Buy" Rating from Canaccord Genuity GroupCanaccord Genuity Group restated a "buy" rating and set a $10.00 price objective on shares of Seres Therapeutics in a report on Wednesday.August 14, 2024 | marketbeat.comStrong Sales and Promising Trials Underpin Buy Rating for Seres TherapeuticsAugust 14, 2024 | markets.businessinsider.comSeres Therapeutics (NASDAQ:MCRB) Lowered to "Sell" at StockNews.comStockNews.com lowered shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research report on Tuesday.August 13, 2024 | marketbeat.comSeres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdatesAugust 13, 2024 | finance.yahoo.comSeres' workers to head to Nestlé on sale of microbiome pill rightsAugust 13, 2024 | bizjournals.com Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Forbes rich list released… #1 to be assassinated? (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now MCRB Media Mentions By Week MCRB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MCRB News Sentiment▼0.860.72▲Average Medical News Sentiment MCRB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MCRB Articles This Week▼42▲MCRB Articles Average Week Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ORIC News Today TERN News Today TRML News Today PHAT News Today PROK News Today ATXS News Today DNA News Today ANNX News Today HUMA News Today PRTC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MCRB) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
